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The paramount importance of repeated left ventricular 
endomyocardial biopsy during the diagnosis of restrict­
ive cardiomyopathy due to AL cardiac amyloidosis
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Amyloidosis is a group of disorders characterised by extracellular deposition of insoluble fibrillary proteins known as amyloid fibrils. Light 
chain amyloidosis (AL) is the most aggressive form and is caused by the accumulation of monoclonal immunoglobulin light chains secondary 
to B-cell dyscrasia. The heart is affected in up to 90% of cases, and more than half of patients present with heart failure (HF) symptoms. Ac-
cumulation of amyloid fibrils causes the myocardial wall to thicken and stiffen leading to the development of restrictive cardiomyopathy 
(RCM). Despite treatment with chemotherapy, the median survival rate in AL amyloidosis and HF is less than six months. A 57-year-old 
female without previous cardiac history sought medical attention due to rapid and progressive dispone and signs of right ventricular (RV) 
congestion (ascites, peripheral oedemas, hepatomegaly). Prior medical history included: chronic kidney disease advanced to the 3rd stage 
(creatinine 158 mmol/L [44–80], eGFR-CKD 39 L/min [> 60]), stroke (ischaemic injury of the thalamus confirmed with magnetic reso-
nance), and Graves-Basedow disease, currently in euthyreosis on Thiamazole 5 mg t.d.s. (TSH 0.134 mIU/mL [0.27–4.2], FT3 5.1 pmol/L 
[3.1–6.8], FT4 25 pmol/L [12–22]). On electrocardiogram characteristic low voltages (< 0.5 mV) of QRS complexes at the limb leads 
were observed. Laboratory tests showed normal blood morphology, grossly elevated NT-proBNP to 7889 pg/mL (< 125), mildly elevated 
CK-MB 34 U/mL (< 25) and hs-troponin T 0.045 ng/mL (< 0.014), and on electrophoresis additional gamma-globulin signal. Free light 
chain ratio of lambda and kappa in serum was abnormal. Urine electrophoresis was negative. Echocardiogram revealed normal left 
ventricular (LV) and RV diameter, both atria grossly enlarged (left and right atrium area 32 cm2 [< 20] and 28 cm2 [< 20], respectively), 
mildly depressed ejection fraction to 50% [> 60]), restrictive physiology of the mitral inflow (E/A 3.2 [< 1.5], E’ lateral 2.5 cm/s [> 7], 
E/E’ 37 [< 13]), high suspicion of pulmonary hypertension (estimated pulmonary artery systolic pressure 60 mm Hg [< 35], distended 
and non-complaint inferior vena cava), and thickened inter-atrial septum (approximately 10 mm [< 3]). The diagnosis of RCM was made 
and she underwent RV endomyocardial biopsy (EMB), which revealed massive fibrosis but was otherwise unspecific. Similarly, bone 
marrow biopsy was negative. Conventional HF treatment with beta-blockers, angiotensin converting enzyme-inhibitors, and diuretics did 
not improve the patient’s status and she was send to our centre. Despite non-diagnostic RV-EMB, the rapid course, laboratory findings, 
and imaging convinced us to undertake LV-EMB. The histopathology revealed a large amount of amorphous substance between tightly 
squeezed myocytes (Fig. 1) and widespread fibrosis (Fig. 2). Characteristic apple-green birefringence of the samples, stained with Congo 
red, were seen under a polarising microscope, which was diagnostic for cardiac amyloidosis. In order to determine the amyloid precur-
sor protein, the immunohistochemistry (anti-bodies against immunoglobulins light chains) has been performed, which confirmed kappa 
and lambda free light chains (Fig. 3). Systemic chemotherapy with bortezomib, melphalan, and dexamethasone was initiated. However, 
due to toxicity, the therapy was changed to low-dose thalidomide, cyclophosphamide, and dexamethasone. Unfortunately, the patient’s 
clinical status gradually deteriorated leading to death five months after the onset of symptoms. 
Figure 3. Immunohistochemistry 
— deposition of kappa and lambda free 
immunoglobulin light chains (patchy 
areas of intense brown colour)
Figure 1. Left ventricle endomyo-
cardial biopsy sample (haematoxy-
lin + eosin staining) — large amount 
of amorphous substance (pale pink) 
compressing surrounding myocytes
Figure 2. Widespread areas of repla-
cement fibrosis (trichrome staining, 
intense blue)
